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BCA-1/CXCL13 expression is associated with CXCR5-positive
B-cell cluster formation in acute renal transplant rejection.
Background. Recent studies showed a crucial role for B cells
in acute renal allograft rejection. It remains largely unknown,
however, which mechanisms lead to the B-cell recruitment into
the allograft. The chemokine CXCL13 and its corresponding
receptor CXCR5 play a central role in B-cell trafficking to sec-
ondary lymphatic tissue and ectopic B-cell clusters in rheuma-
toid arthritis. We therefore investigated the potential role of
CXCL13 and CXCR5 in formation of B-cell clusters in renal
transplant rejection.
Methods. Serial immunohistochemical staining for CXCL13,
CXCR5, and CD20 was carried out in protocol biopsies of 23
patients obtained between day 4 and day 9 after renal transplan-
tation. Intragraft mRNA expression of CXCL13 was assessed
by real-time polymerase chain reaction (PCR) analysis.
Results. Of 23 kidney biopsies obtained between days 4 and 9
after renal transplantation, 13 revealed an acute rejection. Four
of these patients showed a substantial infiltration of the trans-
plant with cluster-forming B cells. By immunohistochemistry
CXCL13 and the corresponding receptor CXCR5 were exclu-
sively detected in areas of B-cell clusters. Intrarenal CXCL13
mRNA expression was 27-fold higher in transplants with B-cell
clusters compared to rejecting allografts without B-cell accu-
mulation (P = 0.011).
Conclusion. We describe a striking colocalization of CXCL13
expression with CXCR5- and CD20-positive B cells in re-
nal transplants undergoing rejection. This is the first study
demonstrating a potential role of CXCL13 and its specific
receptor CXCR5 in recruitment of B cells in renal allograft
rejection.
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Acute renal transplant rejection is generally thought
to be initiated and predominantly mediated by allogen-
activated T cells. However, it has recently been reported
that in some allografts a substantial infiltration of B cells
could be detected in addition to activated T cells. The oc-
currence of intragraft B-cell clusters in acute transplant
rejection was associated with glucocorticoid resistance
and strongly correlated with graft loss [1]. The mecha-
nisms leading to the recruitment of B cells into the allo-
graft are completely unknown.
In general, directional recruitment of inflammatory
cells is mediated by interaction of chemokines, a family of
small chemotactic cytokines, with their corresponding re-
ceptors [2, 3]. The so-called lymphoid chemokine, B-cell–
attracting chemokine-1 (CXCL13), is one of the most im-
portant chemoattractors of B cells [4]. It has been shown
to be responsible for the migration of B cells, bearing
its corresponding receptor CXCR5 into secondary lym-
phatic organs, and was proven to be crucial for lymphoid
tissue development and microarchitecture [5–8]. Further-
more, CXCL13 and CXCR5 play an important role in the
formation of ectopic B-cell clusters in rheumatoid arthri-
tis [10, 11], Sjo¨gren’s syndrome [12, 13], Helicobacter py-
lori-induced gastric lymphoma [14], and central nervous
system lymphoma [15]. Therefore, we investigated the
possible role of this chemokine/chemokine receptor pair
in the recruitment of B cells into renal allografts under-
going early transplant rejection.
METHODS
Tissue samples
Approval for this study was given by the local ethics
committee October 10, 2000 (including the permission
to obtain 2 biopsies from the same patient), and the
study has been conducted according to the Declaration of
Helsinki principles. Tissue samples were obtained from
23 transplant recipients from the transplant center of
the Universita¨tsklinikum Hamburg Eppendorf between
1616
Steinmetz and Panzer et al: BCA-1/CXCL13 and CXCR5 expression in acute renal transplant rejection 1617
Table 1. Baseline characteristics of transplant recipients
Underlying Cold ischemia Donor age Donor Immunosuppressive BANFF Steroid CD20
Patient Age/sex renal disease HLA MM time hours years type therapy grade resistance status
B.D. 55/m Unclear 3 22 61 CD C, M, P 0 –
H.J. 62/f Analgesic NP 2 32 48 CD C, M, P 0 –
Y.D 36/m FSGS 3 22 45 CD C, M, P 0 –
S.M. 35/m Mesangioprol. GN 3 14 57 CD C, M, P 0 –
U.T. 54/f Unclear 2 24 30 CD C, M, P 0 –
H.M. 38/m Unclear 2 15 55 CD C, M, P 0 –
V.G. 38/m IgA NP 3 16 13 CD C, M, P 0 –
R.B. 65/f ADPKD 5 3 68 LD C, M, P, B 0 –
L.K. 65/f Unclear 0 24 73 CD C, A, P 0 –
U.W. 65/m ADPKD 2 6 68 CD C, A, P 0 –
E.S. 66/m Diabetic NP 5 17 70 CD C, S, P IIa No –
H.D. 70/f Hypertensive NP 5 9 70 CD C, R, P IIa Yes –
H.T. 60/f Interstitial nephritis 2 18 54 CD C, M, P Ia No –
N.L. 36/f Reflux NP 1 20 33 CD C, M, P Ia No –
E.M. 56/f Chronic GN 5 2 42 LD C, M, P, B Ib Yes –
D.C. 49/f Chronic GN 6 2 48 LD C, M, P, B Ia No –
D.S. 42/m Chronic GN 3 3 47 LD C, M, P, B IIb Yes –
M.M. 36/m Chronic GN 1 13 55 CD C, M, P Ia No –
M.P. 58/f RPGN 5 22 46 CD C, M, P IIa No –
G.H. 62/f Urothelium Ca 3 23 72 CD C, M, P IIa Yes +
O.A. 29/m Pyelonephritis 3 15 47 CD C, M, P Ib Yes +
M.S. 47/f Pyelonephritis 0 18 17 CD C, M, P IIa Yes +
R.F. 68/f Diabetic NP 6 11 54 CD C, A, P Ia No +
Abbreviations are: MM, mismatches; NP, nephropathy; GN, glomerulonephritis; FSGS, focal segmental glomerulosclerosis; WG, Wegener’s granulomatosis; ADPKD,
autosomal-dominant polycystic kidney disease; CD, cadaveric donor; LD, living donor; C, cyclosporine A; FK, tacrolimus; P, prednisolone; MMF, mycophenolate
mofetil; A, azathioprine; R, rapamycin; S, sirolimus; B, basiliximab; ATG, antithymocyte globulin.
March 2001 and November 2003. Baseline characteris-
tics of the patients are shown in Table 1. Allograft biop-
sies (2 samples/patient) were performed as protocol biop-
sies between day 4 and 9 after renal transplantation. The
first biopsy sample was fixed in formalin, embedded in
paraffin, and stained with hematoxylin and periodic acid-
Schiff (PAS), and was used for histologic examination and
immunohistochemistry. The second specimen was snap
frozen and served for the analysis of chemokine RNA
expression. Classification of transplant rejection was car-
ried out according to the Banff criteria [16]. No biopsy
sample contained evidence of microbiological infections
or lymphoproliferative disorders.
Immunohistochemistry
Immunohistochemical staining for CD20 (L26), CD3
(N1580), vWF (A0082, all DAKO, Germany), CXCL13
(AF801), CCL21 (AF366, both R&D Systems, Germany,
15), and CXCR5 [17] was performed on all 23 biopsies.
Samples were classified as CD20+ or CD20− similarly to
the method described by Sarwal et al [1]. The single high-
power field with the highest CD20-positive cell count
was identified, and biopsies with more than 100 CD20-
positive cells in this high-power field were defined as
CD20+. To identify the high-power field with the highest
CD20-positive cell count, biopsy specimens were stained
for CD20 in serial sections.
Real-time PCR analysis
RNA of the frozen biopsy tissue was isolated accord-
ing to the manufacturer’s protocol (Qiagen, Germany).
Total RNA was reverse transcribed using the Taqman Re-
verse Transcriptase Kit (Applied Biosystems, Foster City,
CA, USA). Real-time polymerase chain reaction (PCR)
analysis was performed in the ABI-Prism 7000 Sequence
Detection System (Applied Biosystems). The following
human PCR primers were used:
hCXCL13-1.1: GCAGCCTCTCTCCAGTCCAA
hCXCL13-1.2: TGGACACATCTACACCTCAAGC
TT
All specific amplicons were normalized against the
housekeeping gene TATA-box binding protein (TBP).
Relative RNA expression of the groups was compared
by Mann-Whitney U test.
RESULTS
Histologic classification of the renal allograft biopsies
In total, 23 patients were included in the study. An
allograft protocol biopsy was obtained from each patient
between day 4 and 9 after renal transplantation. Thirteen
of these 23 biopsies were classified as having an acute
rejection in accordance with the 97 Banff criteria (IA–
IIB), while 10 showed no histologic signs of rejection.
B-cell immunostaining in renal allografts
To detect B cells in the renal allografts, CD20 im-
munostaining was performed. Of the 13 patients with
acute rejection, 4 were classified as CD20+ (>100 B cells/
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high-power field). None of the 10 patients without acute
allograft rejection showed a significant infiltration of
CD20-positive B cells.
Baseline characteristics of transplant recipients
No significant differences existed between the 3 groups
(patients without rejection, CD20−, and CD20+ patients
with rejection) with regard to recipient and donor age,
human lymphocyte antigen (HLA) mismatches, and cold
ischemia time (comparison by Kruskal-Wallis test).
All acute rejections (Banff IA–IIB) were treated with
IV steroid pulses. Interestingly, 75% (3/4) of the CD20+
patients had a steroid-resistant rejection as opposed to
only 33% (3/9) in the CD20− group.
Immunohistochemical staining of CXCL13 and CXCR5
in renal allograft biopsies
Immunohistochemical staining for CXCL13 showed
a striking colocalization with areas of B-cell clusters in
CD20+ allograft biopsies (Fig. 1A to C). No expression
of CXCL13 was detected in samples that were classified
as CD20−. Areas with substantial infiltration of inflam-
Fig. 1 CXCL13 and CXCR5 staining of renal allografts. Serial staining
of renal allografts revealed a striking co-localization of CXCL13 with
areas of CD20-positive cell clusters (A, CD20 100×; B, CXCL13 100×;
C, CXCL13 200×). Note that there is no CXCL13 positivity in areas
with a scattered B-cell infiltration pattern (D, CD20 200×; E, CXCL13
200×). CXCR5 was also exclusively detected in areas of CD20-positive
cell clusters (F, CD20 400×; G, CXCR5 400×; H, CXCR5 1000×). In
areas with a scattered distribution pattern of CD20-positive cells no
signal for CXCR5 could be detected (I, CD20 400×; J, CXCR5 400×).
matory cells negative for CD20 (mainly CD3-positive
T cells) did not show any CXCL13-positive staining
(Fig. 1D and E).
Staining for CXCR5, the specific receptor for CXCL13,
revealed a strong positivity exclusively in areas of cluster-
forming CD20-positive B cells (Fig. 1F to H). Areas with
a scattered B-cell infiltration (Fig. 1I) were negative for
CXCR5 (Fig. 1J). To specifically examine a possible re-
lation of CXCL13-positive B-cell clusters with infiltra-
tion of T cells, immunohistochemistry for the pan T-cell
marker CD3 was carried out. No association of CXCL13
with infiltrating T cells was found in any of the biop-
sies. Even though a substantial number of CD3-positive T
Fig. 2 CD3-positive T cells in areas of CD20-positive B-cell clusters.
Serial staining of CD20-positive B-cell clusters revealed a differential
distribution of CD3-positive T cells and CD20-positive B cells. An over-
lapping expression pattern of CXCL13 with CD20-positive B cells was
found, while CD3-positive T cells were generally present but localized
to different areas (A, CXCL13 100×; B, CD20 100×; C, CD3 100×).
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Fig. 3 CCL21 immunohistochemistry of re-
nal allografts. CCL21 (brown) was detected
by immunohistochemistry in endothelial cells
of rejecting transplants. A general colocal-
ization with mononuclear infiltrates could be
shown, regardless if these contain B-cell ag-
gregates (A, CCL21 200×; B, CD20 200×) or
not (C, CCL21 400×; D, CD20 400×).
Fig. 4 Serial staining of CCL21 and vWF. Serial staining for CCL21
and vWF as common marker for blood vessels revealed that CCL21-
positive vessels were generally negative for vWF. CCL21-positive ves-
sels did not contain any erythrocytes, while these could clearly be seen
in vWF-positive blood vessels (A, CCL21 100×; B, vWF 100×; C, E,
CCL21 200×; D, F, vWF 200×). CCL21-positive vessels in rejecting
renal allografts, therefore, seem to be lymphatics.
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cells were almost always present in the vicinity of CD20-
positive B-cell clusters, they generally located to different
areas (Fig. 2A to C) To determine specific staining of
CXCL13 and CXCR5, immunohistochemistry in lymph
nodes was carried out (data not shown).
Immunohistochemical staining of SLC/CCL21 in
renal allografts
CCL21 was detected in endothelial cells in all 13 biop-
sies of patients with rejecting allografts. As opposed
to CXCL13, a general colocalization of CCL21 with
mononuclear cell infiltrates could be observed regardless
if these contained B-cell clusters or not (Fig. 3A to D).
To further characterize the endothelial cells expressing
CCL21, serial immunohistochemical staining for CCL21
and von Willebrandt Factor (vWF) as a common marker
for blood vessels was carried out. Interestingly, CCL21-
positive vessels were all negative for vWF (Fig. 4A to
F). Furthermore, serial sections revealed that no single
erythrocyte could be found in CCL21-positive vessels,
while they often contained large aggregates of mononu-
clear cells. These findings provide strong evidence that
the CCL21-positive vessels in biopsies of rejecting renal
transplants are lymphatics.
Intrarenal mRNA expression of CXCL13
To analyze the chemokine expression in the renal al-
lografts, RNA was isolated from renal biopsies obtained
between day 4 and day 9 after transplantation, and real-
time PCR was performed. Intragraft mRNA analysis re-
vealed a 27-fold higher CXCL13 expression in patients
with acute renal allograft rejection classified as CD20+
compared to the CD20− biopsies of the remaining 9 pa-
tients with an acute rejection (P = 0.011) (Fig. 5). In con-
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Fig. 5 Intrarenal CXCL13 RNA expression. CXCL13 RNA expression
was analyzed by real-time PCR of isolated RNA from renal biopsies
obtained between day 4 and day 9 after transplantation. Data of the
CD20+ group (patients with acute allograft rejection and B-cell clus-
ters) are expressed as relative RNA expression of the CD20− group
with an acute allograft rejection. Mean ± SD; ∗P = 0.011, CD20+ vs.
CD20− with rejection.
trast, CCL21 expression showed no differences between
these 2 groups (data not shown).
In the biopsies of the 10 patients without rejection,
CXCL13 and CCL21 mRNA expression was in most
cases below the sensitivity level of the real-time PCR.
DISCUSSION
Sarwal et al have recently demonstrated an important
role for B cells in acute transplant rejection [1]. Dense
intragraft B-cell clusters were observed in roughly one
third of rejecting organs. Their functional role in kidney
transplants remains unknown, but seems to be of great
impact as their occurrence was associated with glucocorti-
coid resistance and strongly correlated with graft loss [1].
Stressing these data, we found that in our collective, 75%
(3/4) of the patients with B-cell clusters in their allograft
had a steroid-resistant rejection as opposed to only 33%
(3/9) of patients without. The mechanisms underlying B-
cell recruitment into the allograft and cluster formation
are therefore rewarding objects to study.
In the present investigation, we demonstrated for the
first time a possible role of the chemokine CXCL13 and
its corresponding receptor CXCR5 in B-cell recruitment
into rejecting renal allografts.
CXCL13 was first described as a constitutively ex-
pressed chemokine in secondary lymphatic tissues [4,
5]. It proved to be essential for the complex architec-
ture of lymphoid organs and the interaction of B and
T cells in lymph follicles, resulting in its classification as
so-called lymphoid chemokine [7, 8]. Additional to this
homeostatic function, possible new roles for CXCL13 in
a number of inflammatory settings, including MALT and
CNS lymphoma [14, 15], rheumatoid arthritis [10, 11],
Sjo¨gren’s syndrome [12, 13], and lupus nephritis [18] have
been described. In the present study, we showed a strong
CXCL13 expression in a subset of kidneys from patients
undergoing acute allograft rejection. CXCL13 was ex-
clusively detectable in transplants showing an intragraft
formation of B-cell clusters as early as 6 days after trans-
plantation. A striking colocalization of the B-cell marker
CD20 with CXCR5 bearing cells in areas of CXCL13
expression could be shown in these transplants. Interest-
ingly, neither CXCL13 nor CXCR5 were detected in al-
lografts with a scattered B-cell infiltration. Areas with
substantial infiltration of CD3-positive T cells, which
were generally present in the vicinity of CD20-positive
B-cell clusters, were also negative for CXCL13 and
CXCR5.
Staining for SLC/CCL21, another lymphoid
chemokine that has recently been reported to play
a potential role in renal allograft rejection, revealed a
different expression pattern from CXCL13. Similar to
Kerjaschki et al [19], we detected CCL21 in endothelium
of lymphoid vessels in the vicinity of mononuclear cell
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infiltrates in rejecting allografts. No preference for areas
with B-cell aggregates was found.
Based on these findings, we propose that CXCL13-
mediated attraction of CXCR5-expressing B cells into
rejecting allografts plays a crucial role in early cluster
formation. The infiltrating B cells that show a scattered
distribution pattern might belong to a different subset
of B cells, the recruitment of which is not mediated by
CXCL13 and CXCR5, but may occur via less specific
mechanisms. Some care has to be taken, however, as
internalization or shedding of the receptor after recep-
tor/ligand interaction might occur, which then leads to
immunohistologic negativity, even though these mecha-
nisms are unlikely to happen in all of the scattered B cells
at the same time.
These findings provoke several questions that need to
be addressed in the future. The cellular source of CXCL13
production needs to be determined, as well as stimuli that
lead to its expression. Furthermore, the functional role of
the intragraft B-cell aggregates has to be determined as,
for example, antigen presentation or alloantibody pro-
duction. Most importantly, however, further studies are
necessary to clarify if early intragraft B-cell clusters are
predictors of chronic allograft rejection, and whether
blockade of CXCL13 and/or CXCR5 might prove use-
ful in the treatment of renal allograft rejection.
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